Drugs / AD504
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05071612 | Nov 2021 → Jul 2022 | obstructive sleep apnea syndrome | Apnimed | Completed | Met primary |
| Phase 2 | NCT04645524 | Dec 2020 → Sep 2021 | obstructive sleep apnea syndrome | Apnimed | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD504 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05071612 ↗ |
| Route | Oral | “Oral capsule administered before bed” NCT04645524 ↗ |